✦ LIBER ✦

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

✍ Scribed by Wolfram Pönisch, Marc Andrea, Ina Wagner, Doreen Hammerschmidt, Ute Kreibich, Andreas Schwarzer, Thomas Zehrfeld, Maik Schwarz, Cornelia Winkelmann, Sirak Petros, Anette Bachmann, Tom Lindner, Dietger Niederwieser

Book ID: 113043179
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 349 KB
Volume: 138
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-012-1212-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bendamustine and prednisone in combinati

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

✍ Pönisch, Wolfram; Holzvogt, Bruno; Plötze, Madlen; Andrea, Marc; Bourgeois, Malv 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 331 KB

Bendamustine and prednisone in combinati

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

✍ Pönisch, Wolfram; Moll, Barbara; Bourgeois, Malvina; Andrea, Marc; Schliwa, Thom 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 336 KB

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB

Bortezomib Induction and Maintenance Tre

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

✍ Sonneveld, P.; Schmidt-Wolf, I. G. H.; van der Holt, B.; el Jarari, L.; Bertsch, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 232 KB

Consensus guidelines for the optimal man

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

✍ A. Palumbo; F. Davies; M. Kropff; J. Bladé; M. Delforge; F. Leal da Costa; R. Ga 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 206 KB